AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$UTHR

ROTHBLATT MARTINE A sold $5.1M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $541.64 ($536.26–$546.63, $5.15M total) across 11 trades on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 6, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
high confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishMed
01

Why it matters

The CEO's $5.1M sale could be interpreted as a negative signal, prompting short‑term selling pressure.

02

Market read

First‑time disclosure of a sizable insider sell by the CEO, potentially influencing UTHR's short‑term price action.

03

What to watch

The transaction size is modest relative to the company's market cap and may have minimal price impact.

Relevance 5/10Novelty 7/10Timing: immediate after filing

Background

Form 4 filings disclose insider transactions and are primary sources for material changes in ownership.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

Chairperson & CEO Martine Rothblatt sold $5.1M of United Therapeutics shares via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $5M sale by the CEO is material for a mid‑cap biotech and is disclosed for the first time via Form 4.

Market effects

Sector

May raise questions about United Therapeutics' leadership confidence, potentially affecting other biotech stocks.

Regional

U.S. biotech sector could see slight negative sentiment.

Global

Limited to investors tracking insider activity in biotech.

Counterpoint

What could challenge this read

The sale is pre‑arranged under a 10b5‑1 plan and may not reflect a lack of confidence.

Key entities

  • company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for rare diseases.

  • person
    Martine Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min